TY - JOUR
T1 - The role of chemotherapy in managing chronic lymphocytic leukemia
T2 - optimizing combinations with targeted therapy.
AU - Nastoupil, Loretta J.
AU - Sinha, Rajni
AU - Flowers, Christopher R.
N1 - Funding Information:
Medical writing support was provided by Julie Ponting of Anthemis Consulting Ltd and was funded by Teva Pharmaceutical Industries, Frazer, PA, USA.
PY - 2013
Y1 - 2013
N2 - For many years, alkylating agents were the standard treatment for chronic lymphocytic leukemia (CLL). The advent of purine analogs improved response rates, but not overall survival, and although the monoclonal antibody rituximab is generally active against B-cell malignancies, it has demonstrated limited benefits as monotherapy for the treatment of CLL. However, specific combinations of chemotherapy, antibodies and targeted therapies have demonstrated additive or synergistic activity in CLL cells and deliver substantial clinical benefits. A greater understanding of the actions of chemotherapies and targeted agents on cellular pathways will advance the development of rationally designed combinations corresponding to individual patients' disease profiles.
AB - For many years, alkylating agents were the standard treatment for chronic lymphocytic leukemia (CLL). The advent of purine analogs improved response rates, but not overall survival, and although the monoclonal antibody rituximab is generally active against B-cell malignancies, it has demonstrated limited benefits as monotherapy for the treatment of CLL. However, specific combinations of chemotherapy, antibodies and targeted therapies have demonstrated additive or synergistic activity in CLL cells and deliver substantial clinical benefits. A greater understanding of the actions of chemotherapies and targeted agents on cellular pathways will advance the development of rationally designed combinations corresponding to individual patients' disease profiles.
UR - http://www.scopus.com/inward/record.url?scp=84898353042&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84898353042&partnerID=8YFLogxK
U2 - 10.1586/14737140.2013.818294
DO - 10.1586/14737140.2013.818294
M3 - Review article
C2 - 23919536
AN - SCOPUS:84898353042
SN - 1473-7140
VL - 13
SP - 1089
EP - 1108
JO - Expert review of anticancer therapy
JF - Expert review of anticancer therapy
IS - 9
ER -